Effects of gonadotropin-releasing hormone analogues on ovarian epithelial tumors.
Adelson
M D
MD
Department of Obstetrics Gynecology, State University of New York, Syracuse 13210.
Reece
M T
MT
D000367:Age Factors; D002277:Carcinoma / Q000097:blood / Q000188:drug therapy* / Q000453:epidemiology / Q000503:physiopathology; D002986:Clinical Trials as Topic; D004195:Disease Models, Animal; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D006062:Gonadotropins / Q000009:adverse effects; D017273:Goserelin / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D016729:Leuprolide / Q000494:pharmacology / Q000627:therapeutic use*; D007986:Luteinizing Hormone / Q000097:blood; D008593:Menopause; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000453:epidemiology / Q000503:physiopathology; D011966:Receptors, LHRH / Q000187:drug effects; D012074:Remission Induction; D012307:Risk Factors; D015996:Survival Rate; D016896:Treatment Outcome; D017329:Triptorelin Pamoate / Q000494:pharmacology / Q000627:therapeutic use*
D006062:Gonadotropins; D011966:Receptors, LHRH; D017329:Triptorelin Pamoate; D017273:Goserelin; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D016729:Leuprolide